

Appendix B

DT05 Rec'd PCT/PTO 13 DEC 2004

Abstract of the Disclosure

The invention relates to substituted diaminopyrimidine compounds, which are effective therapeutic compounds for treating diseases and disorders associated with those commonly treated by Protein Kinase C theta (PKCθ) inhibitors.